Shanghai Lidao Pharmaceutical Technology

Shanghai Lidao Pharmaceutical Technology is a clinical-stage biotechnology company dedicated to discovering and developing innovative small molecule drugs for "undruggable" targets. The company focuses on allosteric regulation and protein-protein interactions (PPI), particularly within the RAS/MAPK signaling pathway. Its lead program, LD001, is a highly selective SHP2 inhibitor currently in Phase 1 clinical trials for the treatment of advanced solid tumors. Lidao's proprietary platform integrates structural biology, computational chemistry, and fragment-based drug discovery to address unmet medical needs in oncology. Headquartered in Shanghai, the company is supported by leading venture capital firms including Matrix Partners China and Qiming Venture Partners.